Hikma Pharmaceuticals Plc (OTC:HKMPF)‘s stock had its “equal weight” rating reaffirmed by equities researchers at Morgan Stanley in a research note issued on Tuesday.

Several other analysts have also commented on the stock. ValuEngine raised shares of Hikma Pharmaceuticals Plc from a “hold” rating to a “buy” rating in a research report on Thursday, July 27th. Numis Securities Ltd reissued an “add” rating on shares of Hikma Pharmaceuticals Plc in a research report on Friday, May 19th. Finally, Jefferies Group LLC lowered shares of Hikma Pharmaceuticals Plc from a “buy” rating to an “underperform” rating in a research report on Wednesday, May 17th. Two investment analysts have rated the stock with a sell rating, three have assigned a hold rating and one has assigned a buy rating to the company. The stock has an average rating of “Hold” and an average price target of $27.00.

Shares of Hikma Pharmaceuticals Plc (OTC HKMPF) remained flat at $18.60 during midday trading on Tuesday. The firm has a market cap of $4.48 billion and a price-to-earnings ratio of 28.10. The company’s 50-day moving average is $20.10 and its 200 day moving average is $23.45. Hikma Pharmaceuticals Plc has a one year low of $18.15 and a one year high of $35.00.

ILLEGAL ACTIVITY NOTICE: “Hikma Pharmaceuticals Plc’s (HKMPF) “Equal Weight” Rating Reaffirmed at Morgan Stanley” was first published by American Banking News and is the property of of American Banking News. If you are viewing this article on another site, it was illegally stolen and reposted in violation of US & international copyright laws. The legal version of this article can be viewed at https://www.americanbankingnews.com/2017/08/08/hikma-pharmaceuticals-plcs-hkmpf-equal-weight-rating-reaffirmed-at-morgan-stanley.html.

About Hikma Pharmaceuticals Plc

Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products in solid, semi-solid, liquid, and injectable final dosage forms worldwide. It operates through three segments: Branded, Injectables, and Generic. The Branded segment offers 377 products in 1,125 dosage forms and strengths in the anti-infective, cardiovascular, diabetes, central nervous system (CNS), gastro-intestinal, oncology, respiratory, and miscellaneous therapeutic areas.

Receive News & Ratings for Hikma Pharmaceuticals Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals Plc and related companies with MarketBeat.com's FREE daily email newsletter.